More than half of all patients diagnosed with bladder cancer have low-grade, noninvasive papillary tumors. Current treatment comprises initial transurethral resection (TUR), sometimes with immediate ...
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program In the article that accompanies this editorial, ...
Active surveillance is a safe and cost-effective method to manage patients with recurrent papillary, low-grade, Ta bladder tumours. New long-term data from a large patient cohort confirm previous ...
Investigators in Japan reported that bladder hydrodistention with fulguration of Hunner lesions is potentially useful for treating nocturia in patients with interstitial cystitis. Atsushi Otsuka, MD, ...
Bladder cancer, most frequently caused by smoking and exposure to carcinogens in the workplace, is one of the top 10 most common forms of cancer in men and women in the U.S. More than 70 percent of ...
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Pain control was achieved by TUF in 70.0 percent of 240 patients; 18 patients underwent cystectomy for intractable pain. (HealthDay News) — For patients with interstitial cystitis (IC), transurethral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results